Aastrom Biosciences, a developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, has hired Scott Durbin as chief financial officer (CFO). Durbin brings more than 15 years of healthcare-related banking, financial and corporate development experience to Aastrom.
Durbin was formerly chief operating officer (COO) and CFO of Prescient Medical, which develops diagnostic and therapeutic catheter-based medical devices for the treatment of severe coronary artery disease. While at Prescient, Durbin raised more than US$60m in private equity financing and helped advance the company through early-stage research, development and regulatory approval. Previously, he served as a finance and corporate development consultant for Scios, a Johnson & Johnson subsidiary, and Alteon. Prior to this consulting work, he was an investment banker with Lehman Brothers, where he completed more than US$5bn in financings and merger and acquisition (M&A) transactions for life science companies.
Durbin earned an MPH in health management from the Yale University School of Medicine & School of Management and a BS from the University of Michigan.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more